Characterization of an androgen-responsive, ornithine decarboxylase-related protein in mouse kidney

Kristian M. Silander¹, Päivi Pihlajamaa², Biswajyoti Sahu², Olli A. Jänne³ and Leif C. Andersson¹

1Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland; 2Genome-Scale Biology Program, Research Programs Unit, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland; 3Institute of Biomedicine/Physiology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland

Correspondence: Kristian M. Silander (kristian.silander@helsinki.fi)

We have investigated and characterized a novel ornithine decarboxylase (ODC) related protein (ODCrp) also annotated as gm853. ODCrp shows 41% amino acid sequence identity with ODC and 38% with ODC antizyme inhibitor 1 (AZIN1). The Odcrp gene is selectively expressed in the epithelium of proximal tubuli of mouse kidney with higher expression in males than in females. Like Odc in mouse kidney, Odcrp is also androgen responsive with androgen receptor (AR)-binding loci within its regulatory region. ODCrp forms homodimers and does not heterodimerize with ODC. Although ODCrp contains 20 amino acid residues known to be necessary for the catalytic activity of ODC, no decarboxylase activity could be found with ornithine, lysine or arginine as substrates. ODCrp does not function as an antizyme (corresponding to Cys360 of ODC) appears to destabilize the protein. Evidence for a function of ODCrp was found in ODC assays on lysates from transfected Cos-7 cells where ODCrp repressed the activity of endogenous ODC while Cys363Ala mutated ODCrp increased the enzymatic activity of endogenous ODC.

Introduction

Polyamines are small ubiquitous aliphatic polycations involved in or are essential for fundamental cellular processes and events ranging from cell growth and proliferation to synthesis, function, and stability of macromolecules. Elevated polyamine levels have been linked to tumorigenesis. Thus, the intracellular polyamine concentration is tightly regulated at the levels of synthesis, catabolism, uptake, and excretion. Ornithine decarboxylase (ODC, EC 1.1.1.17) is the first and rate-limiting enzyme in the polyamine synthesis pathway [1-3].

The cellular ODC activity is regulated by a number of growth- and differentiation-inducing stimuli. ODC activity is tightly controlled by changes in the amount of catalytically active ODC protein [4,5]. ODC is catalytically active as a homodimer [6] with the monomers assembled in an antiparallel orientation [7,8]. As the monomers are rapidly dissociating and reassociating [9], ODC is inactivated and degraded by the polyamine-inducible protein ODC antizyme (OAZ) [10-12], which binds ODC monomers and targets them to ubiquitin-independent degradation by 26S proteasome [13-17]. Antizyme inhibitors (AZINs) are ODC-homologous proteins lacking catalytic activity [18]. AZINs, which bind OAZ with a higher affinity than ODC, sequester OAZ, and displace ODC from the ODC–OAZ complex enabling the formation of catalytically active enzyme [19,20]. AZINs that are often induced under same conditions as ODC [21] and are degraded by conventional ubiquitination [22,23].
The mouse protein ODCrp (ODC-related protein, also known as gm853 or ODC2/AZID) was first noticed in a phylogenetic analysis of 229 eukaryotic ODC/AZIN homologs, where the possible functions of the homologs were evaluated based on the conservation of 18 of the 20 amino acid residues found to be critical for the enzymatic ODC activity [24]. Homologs with conserved residues were viewed as potential catalytically active proteins. It was also suggested that homologs may function as antizyme inhibitors or form heterodimers with ODC [24] to inactivate, enhance, or protect the ODC in the complex. In the present study, we characterized the role and functions of ODCrp by investigating its expression profile, protein interactions, and enzymatic activity in the context of the known ODC-OAZ-AZIN regulatory system and possible formation of heterodimer with ODC. ODCrp contains a unique N-terminal extension of 14 amino acids, the possible role of which we also investigated.

Materials and methods

Materials

ODCrp cDNA (F520013M09, gm853) was purchased from Imagenes (Berlin, Germany). The cDNA was subcloned into mammalian expression vectors pCDNA3.1 (Invitrogen, Thermo Fisher Scientific Inc., Waltham, U.S.A.), p3XFLAG-CMV-10, p3XFLAG-CMV-14 (Sigma–Aldrich, St. Louis, Missouri, U.S.A.) and a pCI-neo vector (Promega, Madison, Wisconsin, U.S.A.) modified to produce a C-terminal c-Myc tag. ODCrp cDNA was also modified; the first 13 residues were truncated (ΔA1–13ODCrp) and/or Cys363 was mutated to alanine (ΔA1–13ODCrpC363A and ODCrpC363A). Primers used for cloning and qPCR were purchased from Oligomer Oy (Helsinki, Finland) or IDT (Integrated DNA Technologies, Coralville, Iowa, U.S.A.). The cloned constructs were verified by sequencing.

Two custom-made ODCrp antibodies were used. Rabbit anti-ODCrp[A] antibody, made by Agrisera (Vännäs, Sweden), was raised against the first 25 N-terminal residues of the protein (MTNPSEVKKDLLGVEHLPSEPITL). Rabbit anti-ODCrp[B] antibody, made by GenicBio (Shanghai, China), was raised against residues 305–318 (KKSSLDPGGHRKLA). The anti-ODCrp[A] antibody was used in immunohistochemistry and the anti-ODCrp[B] antibody, which also detects the N-terminally truncated form ΔA1–13ODCrp, used in immunoblotting. All animals were handled in strict accordance with good animal practices as defined by the relevant Finnish animal welfare bodies, and the European Communities Council directive (86/609/EEC). The specificities of both antibodies were verified by SDS/PAGE and immunoblotting, and no cross-reactivity with ODC, AZIN1, or antizyme inhibitor 2 (AZIN2) was observed.

Experimental animals

ICR mice (10- to 12-weeks old) were used. Intact males, orchietomized males, and female mice were injected subcutaneously with testosterone (T, 1 mg/mouse/day in 0.1 ml mineral oil) or vehicle. Orchietomized males received T four days after the operation. Gene expression analyses were performed with mice treated with T for 3 days. ChIP assays were performed 2 h after a single T injection. All animal experiments were approved by the Finnish Review Board for Animal Experiments and performed according to the guidelines for animal experiments at the University of Helsinki (permit number EL/2008-09035/Ym23). The mice were killed by carbon dioxide inhalation and different organs were either snap-frozen in liquid nitrogen for RNA isolation or fixed in 10% buffered formalin (Sigma–Aldrich) and embedded in paraffin for immunohistochemistry.

ChIP and ChIP-sequencing

Minced fresh mouse tissues were cross-linked in 1% formaldehyde (Merck KGaA, Darmstadt, Germany) at room temperature for 20 min. After washing twice with ice-cold PBS, tissues were homogenized in hexylene glycol buffer to isolate a crude nuclear fraction [25]. Sonication (Sonicantor 3000, Misonix, Inc., Farmingdale, U.S.A.) was performed in 500 μl of RIPA buffer to yield chromatin fragments of 100–500 bp in size. Immunoprecipitation was carried out with polyclonal anti-androgen receptor (AR) antibody or normal rabbit IgG (sc-2027, Santa Cruz, Dallas, U.S.A.) as previously described [26]. After reverse cross-linking overnight at 65°C, immunoprecipitated and input DNA was purified using PCR purification kit (Qiagen, Hilden, Germany) and eluted in 100 μl of elution buffer. For ChIP qPCR, 5 μl of ChIP or input DNA was used in each reaction with SYBR Green master mix (Roche, Basel, Switzerland) and specific primers (Odcrp –4 kb; forward primer 5’-AGGTCAGAGTTCTCTGTT, reverse primer 5’-GAGACGCTTTGGGCCTGAT; Odcrp +30 kb; forward primer 5’-CAGCCAGATGCAGTTTTC, reverse primer 5’-TTCCAGGCTTTGAGTTTGT). Results from IP samples were normalized to respective input sample, and the results (mean ± S.E.M.) for four replicates are shown as percent of input. DNA libraries from ChIP samples were prepared according to Illumina’s instructions and sequenced using Illumina Genome Analyzer II. Peak calling
was performed using MACS algorithm [27] and sequencing tag pile-up was visualized using Integrative Genomics Viewer [28].

**qPCR**
Snap-frozen mouse organs (kidney, liver, brain, lung, spleen, heart, prostate, and testis) were powderized and RNA was isolated using TRI Reagent (RNA/DNA/Protein isolation reagent, Molecular Research Center Inc., Ohio, U.S.A.) according to the manufacturer’s instructions. RNA (1 μg) was used to produce cDNA (High Capacity RNA-to-cDNA Kit, Applied Biosystems, Life Technologies, Thermo Fisher Scientific Inc.) according to manufacturer’s instructions. The cDNA was then used as template in qPCR (LightCycler, Roche) with enzyme mix (SYBR Green/ROX qPCR Master Mix (2×), Thermo Scientific, Thermo Fisher Scientific Inc.) and specific primers (ODCrap: forward primer 5’-ACACACCTGAGGCTACAGA and reverse primer 5’-TCCTGGATCGGAAAGACT, β2M: forward primer 5’-ATGTCTTCGATCCAGTAGAC and reverse primer 5’-GCTATCCGAAAAACCCTCA). Sample quantitations were normalized using the invariant endogenous control β2M. Finally, the results (mean ± S.D.) of three biological replicates were scaled to the result of untreated male control.

**Immunohistochemistry**
Five-micrometer thick sections from formalin fixed and paraffin-embedded kidneys were stained with 1:1200 diluted rabbit anti-ODCrap[A] antibody and with its preimmune serum as control using Vectastain Elite ABC Kit (Vector Laboratories Inc., Burlingame, U.S.A.) according to the manufacturer’s instructions essentially as described [29]. Light microscope photographs were taken with an Olympus BX51 microscope (Olympus Optical, Tokyo, Japan) and a Nikon Digital Sight DS-5M camera (Nikon Corporation, Tokyo, Japan) using NIS-Elements F2.30 software (Nikon Corporation). Digital image processing was performed with PhotoScape v3.6.1 (Mooii Tech, Informer Technologies Inc., Los Angeles, U.S.A.).

**Cell cultures and transfections**
Cos-7 cells were cultured in DMEM medium. ODC-deficient CHO cells (a kind gift from Dr Lo Persson, Lund, Sweden), devoid of endogenous ODC activity, were cultured in RPMI-1640 medium supplemented with putrescine. Both media also contained 10% (v/v) FBS (Gibco, Life Technologies, Thermo Fisher Scientific Inc.), L-glutamine and penicillin and streptomycin. ODC-deficient CHO cells were plated without putrescine 24 h before transfection. Cells were transfected with the desired plasmids using the FuGENE6 transfection reagent (Promega) according to the manufacturer’s instructions. In co-transfection experiments, the transfection mix contained equal amounts of both plasmids. Production of the transfected proteins was verified by SDS/PAGE and immunoblotting.

**In-vitro translation**
Radiolabeled in vitro translated proteins were produced using an In-vitro translation (IVT) kit (TNT Coupled Reticulocyte Lysate System, Promega) according to the manufacturer’s instructions with L-[35S]-methionine (PerkinElmer, Waltham, U.S.A.). Samples of the translated proteins and Amersham Rainbow [14C] methylated protein molecular weight marker (Amersham Biosciences, GE Healthcare Life Sciences, Chicago, U.S.A.) were separated by SDS/PAGE (12% gel). The gel was fixed for 30 min in 30% methanol and 10% acetic acid solution and incubated for 1 h in Amplify Fluorographic Reagent (Amersham Biosciences). The gel was vacuum dried (Model 853 Gel Dryer, Bio–Rad, Hercules, U.S.A.) on to filter paper for 2 h at 80°C and used to expose an X-ray film (FUJI) overnight.

**Degradation assay**
Protein degradation assay was performed as described previously [23]. Of the in-vitro translated proteins used, only ODC was radiolabeled. As a negative control, IVT lysate without translated proteins was mixed with radiolabeled ODC. The reactions were set up by mixing 1 μl OAZ with 14 μl ODCrap/Δ1-13ODCrap/ΔZIN1/lysate for 10 min at room temperature. ODC (2 μl) was added to the mixture, which was kept at 4°C for 5 min, whereafter prewarmed (37°C) ATP-regenerating buffer (50 mM Tris/HCl, pH 7.5, 5 mM MgCl2, 2 mM DTT, 0.5 mM ATP, 10 mM p-creatine, and 5 μg/ml creatine kinase) was added to a total volume of 60 μl. The reactions were incubated at 37°C and 5 μl samples were taken after 0, 10, 30, and 1 h. The samples were immediately mixed with 2 x Laemmli sample buffer + 2-mercaptoethanol and separated by SDS/PAGE (12% gel). Radiolabeled ODC was visualized by fluorography.
Catalytic activity assay

The decarboxylase activity assay was performed as described previously [23] by quantitating the release of $^{14}$CO$_2$ from the radiolabeled substrates [1-$^{14}$C]ornithine, [1-$^{14}$C]arginine, or [1-$^{14}$C]lysine (PerkinElmer). Reactions with in-vitro translated proteins contained 2 µl ODC, 1.4 µl OAZ, and 10 µl $\Delta_{1-15}$ODCrp/ODCrp/AZIN1 in different combinations. In the assays with cell lysates, Cos-7 or ODC-deficient CHO cells were transiently transfected with the empty pCDNA3.1 vector or constructs containing cDNA for ODC, AZIN1, ODCrp, $\Delta_{1-15}$ODCrp, ODCrpC363A, or $\Delta_{1-15}$ODCrpC363A. Transfected cells were collected and handled as described previously [30].

Immunoprecipitation

In co-precipitation experiments, Cos-7 cells were co-transfected with plasmids producing FLAG-tagged and Myc-tagged proteins. Myc-tagged proteins were immunoprecipitated with 4 µg mouse monoclonal anti-Myc antibody (Sigma–Aldrich) and protein G-agarose (Roche) using an immunoprecipitation kit (Roche) according to the manufacturer’s instructions. Alternatively, FLAG-tagged proteins were immunoprecipitated with 4–5 µg mouse monoclonal anti-FLAG antibody (Sigma–Aldrich) and protein G-agarose. Finally, agarose pellets were suspended in 20 µl 2× Laemmli sample buffer + 2-mercaptoethanol, heated at 95°C for 5 min and separated by SDS/PAGE. Co-precipitated FLAG-tagged proteins were detected by immunoblotting with rabbit polyclonal anti-FLAG antibody (Sigma–Aldrich). Alternatively, co-precipitated Myc-tagged proteins were detected by immunoblotting with rabbit polyclonal anti-Myc antibody (MBL, Medical & Biological Laboratories Co., Ltd, Nagoya, Japan). In the ubiquitination experiment, Cos-7 cells were transfected with plasmids encoding FLAG-tagged proteins that were immunoprecipitated with mouse anti-FLAG antibody and analyzed by immunoblotting with rabbit anti-ubiquitin antibody (DAKO).

Treatment with cycloheximide

Cos-7 cells were transfected with ODCrp-pCDNA3.1 or ODCrpC363A-pCDNA3.1 constructs and treated with 50 µg/ml cycloheximide. Samples were collected after 1, 3, and 5 h of treatment and lysed on ice in 60 µl cold Pawson lysis buffer for 10 min. Supernatants of centrifuged lysates were recovered for SDS/PAGE and analyzed by immunoblotting.

Immunoblot analyses

Samples separated by SDS/PAGE were transferred to immunoblot membranes (Immobilon-FL transfer membranes, Merck Millipore, Darmstadt, Germany). After incubating the membranes with desired primary antibodies, the protein bands were visualized by incubating with appropriate fluorescent secondary antibodies; donkey anti-mouse (IRDye 800CW, Odyssey, LI-COR Biosciences, Lincoln, U.S.A.) and/or goat anti-rabbit (Alexa Flour 680, Invitrogen). All antibodies were diluted in 1:1 PBS + odyssey blocking buffer (LI-COR Biosciences). Finally, the membranes were scanned (Odyssey) and the images analyzed (ImageStudio Ver 3.1, LI-COR Biosciences).

Statistical analysis

The statistical significance was calculated by unpaired Student’s t test, and a value of $P<0.05$ was considered significant. In the figures, the statistical significance of differences between two samples is indicated by a square bracket and an asterisk (*), except for Figure 7, which contains brackets only.

Multiple sequence alignment

The multiple sequence alignment with mouse proteins ODCrp, ODC, AZIN1, and AZIN2 was performed with Clustal Omega 1.2.2 (ebi.ac.uk/Tools/msa/clustalo/). The GenBank IDs for the sequences used were AK143920.1, J03733.1, BC043722.1, and NM_172875.4, respectively. The sequence identities of the pairwise alignments were obtained using EMBOSS Needle (ebi.ac.uk/Tools/psa/emboss_needle/) with the default BLOSUM62 matrix.

Results and discussion

ODCrp and ODC/AZIN sequence alignment

The mouse ODCrp was first noticed in a phylogenic analysis of ODC-like sequences [24]. We aligned the sequences of mouse ODCrp, ODC, AZIN1, and AZIN2 in an attempt to uncover the function of ODCrp. As previously reported by Ivanov et al. [24], the following 20 amino acid residues are most critical for the catalytic ODC activity: Lys$^{69}$ binds pyridoxal-5’-phosphate [31], residues Asp$^{88}$, Glu$^{94}$, Arg$^{154}$, His$^{197}$, Ser$^{200}$, Gly$^{235-237}$, Glu$^{274}$, Arg$^{277}$, Asp$^{332}$, and Tyr$^{389}$ stabilize the bound pyridoxal-5’-phosphate [7,8], residues Asp$^{332}$ and Asp$^{361}$ interact with the substrate [7,32],
nucleophilic attack by Cys\textsuperscript{360} control the formation of the product [33], while Phe\textsuperscript{397} binds the 1-CO\textsubscript{2} [34]. Residues Gly\textsuperscript{177} and Gly\textsuperscript{387} have structural roles within the monomer [35], while residues Lys\textsuperscript{169}, Arg\textsuperscript{277}, Asp\textsuperscript{332}, Asp\textsuperscript{364}, and Tyr\textsuperscript{383} are important for the dimerization (Figure 1) [7,36]. Based on the conservation of the 20 functionally critical residues in ODcrp, Ivanov et al. [24] suggested that ODcrp might be catalytically active and able to form a dimer.

OAZ binds to the 117–140 region of ODC [13]. The residues Gln\textsuperscript{119}, Ala\textsuperscript{124}, Asn\textsuperscript{125}, Gln\textsuperscript{129}, Glu\textsuperscript{136}, Val\textsuperscript{137}, and Met\textsuperscript{140} of human ODC are most important for OAZ binding [37]. Lys\textsuperscript{141} and Phe\textsuperscript{397} also interact with residues of OAZ, while Lys\textsuperscript{69}, Lys\textsuperscript{92}, and Tyr\textsuperscript{233} come in close proximity to the surface of OAZ [19]. Human and mouse ODC proteins differ at only two residues within the 117–140 region, where Asn\textsuperscript{125} and Val\textsuperscript{137} of human ODC are substituted for Ser\textsuperscript{125} and Ile\textsuperscript{137} in mouse ODC. In ODcrp, only 14 of the 24 residues of the OAZ-binding motifs are conserved, including only three (Ala\textsuperscript{124}, Gln\textsuperscript{129}, and Glu\textsuperscript{136}) of the seven most important residues. However, of the other residues interacting with or coming in close proximity to OAZ, all except for Lys\textsuperscript{92} are conserved in ODcrp (Figure 1). AZINs have a higher affinity for OAZ than ODC [19]. The higher affinity is mediated by differences at residues 125 and 140, where serine and methionine of ODC are replaced by two lysine residues in AZIN1 [38]. In AZIN2, only the former lysine is conserved, while the latter is changed to alanine. It is unlikely that ODcrp has an AZIN-like affinity for OAZ, as in ODcrp these residues are arginine and isoleucine, respectively. ODC has two PEST sequences [39] that are recognized by the proteasome after OAZ binding to ODC [14]. The PEST sequences consist of regions 293–333 and 423–449, of which the latter is more important for the OAZ-mediated degradation [40]. In ODcrp, the region of the first PEST sequence has undergone many changes and is partially missing, while the latter region is lacking entirely (Figure 1). The mutated OAZ-binding motif suggests that ODcrp does not interact with OAZ, which together with the missing PEST sequences suggest that ODcrp degradation is likely to be initiated by ubiquitination.

The N- and C-terminal differences between ODcrp and ODC may not affect the functions of ODcrp, as those regions are located on the outer surface of the folded protein away from the active sites or dimer interface [41,8]. It is plausible to assume that ODcrp functions as an independent enzyme that does not interact with OAZ. Alternatively, ODcrp could serve as an ODC enhancer by binding ODC to form a catalytically active and/or a degradation-resistant heterodimers.

**Tissue expression and androgen responsiveness of Odcrp**

According to the UniGene expressed sequence tag (EST) profile (Mm.387701) [42], Odcrp is mainly expressed in kidneys and to a lesser extent in liver. The result of qPCR experiments on RNAs from kidney, liver, brain, lung, spleen, heart, prostate, and testis showed that Odcrp mRNA is almost exclusively expressed in kidney, which is in-line with the EST profile. Although some expression was also found in the brain, the Odcrp mRNA level in the brain was only approximately 3% of that in the kidney. Odcrp mRNA level in the liver was less than 0.03% of that in the kidney (results not shown).

Odcrp is known to be androgen-inducible in mouse kidney [43–45]. qPCR experiments showed that the steady-state Odcrp mRNA level was approximately two-fold higher in male than in female kidneys. The difference in ODcrp expression in male and female kidneys was statistically significant (P < 0.05) in a sample size of 17 male and 19 female mice. Treatment of ICR mice with 1 mg T for 3 days increased accumulation of Odcrp mRNA approximately 5.3-fold in male and 4.4-fold in female kidneys (Figure 2).

In vivo ChIP-seq experiments [46] were performed to examine whether there are AR-binding sites adjacent to the Odcrp locus to support the notion that androgen induction of Odcrp mRNA accumulation is a transcriptional event. AR binding in vivo to renal chromatin in the absence of androgen was marginal, while T treatment resulted in loading of AR on to specific sites adjacent to the Odcrp locus. More specifically, there were several AR binding events at +30 kb and -4 kb regions of the Odcrp transcription start site after 2 h of T exposure (Figure 3A). AR loading on to the two Odcrp regulatory regions was validated by using direct ChIP assays, and the results showed that androgen exposure result in approximately ten-fold enrichment of AR binding in vivo at both loci in murine kidneys (Figure 3B).

Sections from kidneys of T treated and control male mice were stained with rabbit anti-ODCrp[A] antibody. In kidneys of control mice, ODcrp antigen level was most abundant in the subcapsular area and in the inner part of the cortex closest to the medulla, where the staining was strongest in the epithelial cells of the proximal tubules (Figure 4A). In kidneys of T-treated mice, ODcrp expression was seen throughout the whole cortex. Similar to ODC and AR expression [46,47], the staining of ODcrp antigen was strongest in the epithelial cells of the proximal tubules (Figure 4B). These cells also increased in size (Figure 4B), a known hypertrophic effect of androgens in mouse kidney [48]. Androgen regulation of Odc does not require catalytic ODC activity [44], and subsequent polyamine accumulation is not needed for androgen-induced hypertrophy of mouse kidney [44,49]. The effect of androgen action in mouse

© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC By).
### Figure 1. Multiple sequence alignment of the mouse ODCrp, ODC, AZIN1, and AZIN2

The 20 amino acid residues most critical for the catalytic ODC activity are marked in dark gray. The small arrow indicates the residue Cys\(^{363}\) in ODCrp and Cys\(^{360}\) in ODC. The antizyme-binding region is marked by a square. The five most important residues within the antizyme-binding region of ODC are marked in black, while the two residues of AZIN1 enhancing its affinity toward antizyme are marked in dark gray. Residues coming into close proximity with the surface of antizyme in the ODC-antizyme complex are marked in gray. Two of these residues also belong to the 20 most critical residues marked in dark gray, in that case, a gray dot (.) was placed above them. The two PEST sequences of ODC are marked with underlining bars, with the most important region marked in by a bolder bar. The alignment shows that ODCrp contains all the residues needed for catalytic activity, while the regions needed for antizyme binding and antizyme-mediated degradation are either mutated or missing. The alignment of the antizyme-binding regions of mouse and human ODC is also shown at the bottom. The two differing residues within the antizyme-binding region of mouse and human ODC are marked in gray.
Bioscience Reports (2017) BSR20170163
DOI: 10.1042/BSR20170163

Figure 2. Odcrp mRNA is androgen responsive in mouse kidney
Treatment of mice for 3 days with testosterone (+T, 1 mg/day) increased Odcrp mRNA accumulation by 5.3-fold in male and 4.4-fold in female kidneys as measured by qPCR. Results shown are the mean + S.D. of three replicates.

Figure 3. AR is loaded on to regulatory loci of Odcrp on mouse kidney chromatin
AR loading in vivo was minimal in castrated male mice (Cast), and testosterone exposure induced approximately ten-fold enrichment of AR loading on to the −4 kb and +30 kb regulatory regions. Panel (A) shows the AR-binding events within and around the Odcrp locus as determined by ChIP-seq analysis. Panel (B) shows the results of direct ChIP assays on AR loading of four biological replicate samples normalized to the respective input samples (mean + S.E.M.).

Kidney comprises several hundreds of genes that are up- or down-regulated by androgens [46,50], and Odcrp belongs to the category of up-regulated genes. Of note, genes involved in DNA replication or cell proliferation are not regulated by androgens in mouse kidney as opposed to mouse prostate [46].

Catalytic activity and dimer formation of ODCrp
Dimerization is required for the catalytic ODC activity [6]. To investigate whether ODCrp is also capable of dimerization, Cos-7 cells were co-transfected with two ODCrp cDNA constructs, one producing a FLAG tag and the other a Myc tag. FLAG-tagged proteins were recovered by immunoprecipitation from cell lysates and analyzed by SDS/PAGE and immunoblotting with anti-Myc antibody. ODCrp was found to form dimers similar to ODC (Figure 5). In addition to native ODCrp, the modified forms Δ1-13ODCrp, ODCrpC363A, and Δ1-13ODCrpC363A also dimerized. In
Figure 4. Immunohistochemically stained sections of mouse kidney

All three panels (A, B, C) show a 50 × magnified section of the whole cortex (a) as well as 200 × magnified close ups of the subcapsular area (b) and inner cortex bordering the medulla (c). In normal male kidney (A), the presence of ODCrp antigen is confined to epithelial cells of the proximal tubules closest to the medulla and in the subcapsular area. Treating of male mice with T (1 mg/day) for 3 days (B) induced elevated ODCrp expression in the whole cortex, while still being most prominent in the proximal tubules and subcapsular area. T also brought about hyperthrophy of proximal tubule epithelial cells. Panel (C) shows a kidney of T-treated male stained with preimmune serum. Nuclei were counterstained with hematoxylin.

Figure 5. ODCrp dimers co-immunoprecipitated and visualized by immunoblotting

Cos-7 cells were co-transfected with cDNAs encoding tagged proteins. The positive ODC-dimer control and two negative controls with only Myc-tagged ODCrp forms are on the left side of the markers (M). On the right side are the ODCrp samples with both FLAG- and Myc-tagged proteins. The FLAG-tagged proteins were immunoprecipitated with mouse anti-FLAG antibody, and co-precipitated Myc-tagged proteins were visualized by probing with rabbit anti-Myc antibody. The result shows that all four ODCrp variants formed homodimers.

\[ \Delta_{1-13}\text{ODC} \text{rp}, \text{the unique N-terminal extension was deleted while in ODC} \text{rp}_{\text{C363A}}, \text{the Cys}^{363} \text{ is mutated to alanine. Cys}^{363} \text{ of ODC} \text{rp corresponds to Cys}^{360} \text{ of ODC.} \]

We next investigated whether ODCrp catalyzes decarboxylation of ornithine. ODC-deficient CHO cells that are devoid of endogenous ODC activity [51] were transfected with cDNA constructs encoding different ODCrp variants or mouse ODC as positive control. Immunoblotting of the lysates from transfected cells showed protein expression with all cDNA constructs. However, in the ODC assay, only lysates from the cells transfected with ODC cDNA displayed catalytic activity above background (results shown in Supplementary Figure S1), which means that ODCrp itself does not display measurable decarboxylase activity under the conditions used for a conventional ODC assay.

Since ODCrp did not exert catalytic ODC activity, we tested whether ODCrp was able to catalyze decarboxylation of other substrates like lysine and arginine [52]. Constructs with different ODCrp cDNA variants were transfected into Cos-7 cells that are devoid of endogenous arginine and lysine decarboxylase activity. Lysates from transfected Cos-7 cells were assayed for lysine and arginine decarboxylase activity under the same conditions as that for the ODC assay. Since no positive controls were available for lysine and arginine decarboxylase assays, lysates of Cos-7 cells transfected with an ODC cDNA construct were assayed for ODC activity to serve as a positive control. No lysine
or arginine decarboxylase activity was detected with the ODCrp constructs used, indicating that the substrate of ODCrp is neither lysine nor arginine (results shown in Supplementary Figures S2 and S3).

Ivanov et al. [24] originally suggested that ODCrp might form a heterodimer with ODC. To investigate this possibility, we co-transfected Cos-7 cells with cDNA constructs producing Myc-tagged (mouse) ODC and FLAG-tagged ODCrp proteins. As a positive control, Cos-7 cells were co-transfected with constructs producing Myc-tagged (mouse) ODC and FLAG-tagged (mouse) ODC. As a negative control, Cos-7 cells were co-transfected with Myc-tagged (mouse) ODC and FLAG-tagged (human) AZIN1. The Myc-tagged proteins were recovered by immunoprecipitation from lysates and analyzed by SDS/PAGE and immunoblotting with anti-FLAG antibody. Neither ODCrp nor Δ1–13ODCrp co-precipitated with ODC under the conditions where ODC-Myc co-precipitated with ODC-FLAG (Figure 6A). A reciprocal immunoprecipitation yielded the same result (shown in supplementary Figure S4 A,B). Thus, no evidence for formation of stable heterodimers between ODC and ODCrp was obtained.

Although ODCrp neither catalyzed ornithine decarboxylation nor formed dimer with ODC, it could nevertheless affect endogenous ODC activity by interacting with other endogenous proteins or by acting upon a substrate that is naturally present in the cells. To examine this possibility, we performed an ODC assay with lysates from Cos-7 cells transfected with cDNA constructs for the different ODCrp variants and with mouse ODC cDNA as positive control. Human AZIN1, which should bind the endogenous green monkey OAZ1 (human and green monkey OAZ1 are 99% identical), was also included to mark the highest activity achievable with endogenous ODC. Compared with the vector control, the presence of ODCrp and Δ1–13ODCrp had a weak but statistically significant repressing effect.
on the total ODC activity. This confirmed that ODCrp itself did not have any intrinsic ODC activity. On the contrary, expression of the mutated and ‘inactive’ counterparts ODCrpC363A and Δ1-13ODCrpC363A had a slight but statistically significant enhancing effect on the total ODC activity (Figure 7). The activities of the lysates with the different ODCrp forms were smaller than with AZIN1 and only approximately one-tenth of that with the positive control ODC (not shown), suggesting that the different ODCrp forms somehow affected the catalytic activity of endogenous ODC. The intact and mutated variants of ODCrp should essentially have the same molecular interactions, with the difference that the mutated forms should not catalyze decarboxylation [33]. If the concentration of this putative substrate is low and/or only a small fraction of it is free and metabolically available, as is the case with polyamines [53], and if both the intact and mutated ODCrp forms bind the substrate but only the intact forms complete the reaction, it could explain why the total ODC activity is repressed in the presence of ODCrp and Δ1-13ODCrp and increased in the presence of ODCrpC363A and Δ1-13ODCrpC363A. These opposite effects seen with the intact and mutated forms are unlikely to result from differences in protein levels (further elaborated below) or cell proliferation, as immunoblotting revealed the presence of all ODCrp forms at similar total protein concentrations (shown in Supplementary Figure S5).

**ODCrp degradation and stability**

Unlike ODC, ODCrp is likely to be degraded by ubiquitination as both the OAZ-binding motifs and the two PEST sequences are impaired. To investigate the degradation pathway of ODCrp, FLAG-tagged proteins were recovered by immunoprecipitation from lysates of transfected Cos7-cells and analyzed by SDS/PAGE and immunoblotting with antiubiquitin antibody. ODCrp was found to be ubiquitinated like AZIN1 (Figure 8) [22]. No difference was observed between ODCrp and Δ1-13ODCrp.

When verifying the amounts of transfected proteins in the ODC assay samples by SDS/PAGE and immunoblotting, we observed that the levels of ODCrpC363A and Δ1-13ODCrpC363A appeared lower than the levels of ODCrp and Δ1-13ODCrp. To examine the reason for this finding, cells transfected with ODCrp or ODCrpC363A constructs were treated with 50 μg/ml cycloheximide, lysed, and the lysates were analyzed by immunoblotting with anti-ODCrp[β]

---

**Figure 7. ODC assay on transfected Cos-7 cells**

Transfected Cos-7 cells were lysed directly in the assay buffer. The ODC activities of ODCrp, Δ1-13ODCrp, ODCrpC363A, Δ1-13ODCrpC363A, AZIN1, and vector control were all of the same order of magnitude. As compared with the vector control, the endogenous ODC activity was decreased by the presence of the ‘catalytically intact’ ODCrp forms and enhanced by the C363A mutated forms. Results are shown as the mean ± S.D. of four replicates taken from separate cell culture dishes. All brackets indicate statistically significant differences.
Figure 8. Immunoprecipitated proteins blotted with anti-ubiquitin antibody

FLAG-tagged proteins produced in Cos-7 cells were immunoprecipitated with mouse anti-FLAG antibody. The first four samples were immunoblotted with rabbit anti-ubiquitin antibody to show that ODCrp and δ1–13ODCrp were ubiquitinated like the positive AZIN1 control, and the non-ubiquitinated ODC-FLAG served as negative control. The fifth sample is the ODC control probed with anti-FLAG antibody.

Figure 9. Stability of ODCrp as determined by cycloheximide treatment

Cos-7 cells transfected with ODCrp or ODCrp C363A constructs were treated with cycloheximide (50 μg/ml) for 0, 1, 3, and 5 h. The relative amounts of ODCrp and ODCrp C363A at different time points were quantitated in relation to respective GAPDH bands on the immunoblot. The results are shown as the mean ± S.D. of the band intensity of four sample replicates.

The results showed that the mutation of Cys^{363} (corresponding to Cys^{360} of ODC) to alanine caused destabilization of ODCrp (Figure 9), suggesting that this residue is of importance for the functional role and/or conformation of the protein.
Interaction between ODCrp and antizyme and the effect on ODC degradation

In ODC (and AZIN1), the residues 117–140 constitute the OAZ-binding motif [13]. Despite the fact that the sequence alignment showed that only 14 of these residues are conserved in ODCrp, an interaction between ODCrp and OAZ could still be mediated by residues outside of the OAZ-binding region. We performed a co-immunoprecipitation experiment to investigate whether ODCrp displays AZIN functions by binding to OAZ. Cos-7 cells were co-transfected with constructs producing FLAG-tagged ODCrp or AZIN1 and Myc-tagged OAZ. The Myc-tagged OAZ was recovered by immunoprecipitation from the lysates and analyzed by SDS/PAGE and immunoblotting with anti-FLAG antibody. There was no evidence for direct binding between ODCrp and OAZ, whereas AZIN1 co-precipitated with OAZ (Figure 6A, last two lanes).

The possibility exists that ODCrp inhibits the OAZ-mediated degradation of ODC without direct binding to OAZ. It is also possible that the interaction between ODCrp and OAZ or between ODCrp and ODC occurs even if it cannot be found by co-immunoprecipitation. To investigate this, we performed degradation assays with in-vitro translated proteins. The results showed that neither ODCrp nor OAZ inhibited ODC degradation under the conditions where AZIN1 blocked ODC degradation (Figure 10). Thus, since ODCrp does not directly bind OAZ or protect ODC from OAZ-mediated degradation, it is very unlikely that ODCrp displays AZIN functions in vivo.

To further investigate functional interactions between ODC, OAZ, ODCrp, and AZIN1, we performed ODC assays with in-vitro translated proteins. The results showed that: (i) ODCrp did not release ODC from OAZ-mediated inhibition under conditions where AZIN1 displayed such a function, and (ii) the activity of 10 μl IVT ODCrp was very close to that of 10 μl AZIN1 and less than approximately one-third of the activity of 2 μl ODC, suggesting that ODCrp was devoid of measurable intrinsic ODC activity under the conditions where the positive ODC control catalyzed.
Figure 11. ODC activity assay with IVT proteins
The assay sets contained 2 μl ODC, 1.4 μl OAZ, and 10 μl ODCrp/Δ1-13ODCrp/AZIN1 in different combinations. The activity of 10 μl ODCrup and Δ1-13ODCrp was similar to the activity of 10 μl AZIN1 and lower than that of 2 μl ODC, suggesting that ODCrup and Δ1-13ODCrp have no intrinsic ODC activity. Unlike AZIN1, ODCrup or Δ1-13ODCrp did not block the antizyme-mediated inhibition of ODC, as the measured activity of the reaction set containing all three components was essentially the same as the calculated additive activity of the two separate ‘basal’ reactions (as the values on the bars indicate). Thus, ODCrup is not an AZIN. Results are shown as the mean + S.D. of three to five reactions per set.

ornithine decarboxylation as expected (Figure 11). We could not get evidence for any functional or regulatory role of the unique N-terminal extension ODCrup.

Conclusion
ODCrup is an androgen-inducible protein specific to mouse kidney, where its expression is most prominent in epithelial cells of the proximal tubules closest to the medulla. ODCrup is neither an AZIN nor a direct ODC enhancer, as no interaction could be shown between ODCrup, and OAZ or ODC. While ODCrup forms dimers, it does not catalyze decarboxylation of ornithine, lysine, or arginine. Its putative substrate remains to be identified. However, ODCrup displayed a small but significant regulatory influence on the catalytic activity of endogenous ODC. Last, no indication for a functional or regulatory role of the unique N-terminal extension ODCrup was uncovered.

Acknowledgements
We thank Dr Kristiina Kanerva, PhD for valuable suggestions and critical review of the manuscript.

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Author contribution
K.M.S. and L.C.A. designed the experiments and wrote the paper. O.A.J. contributed expert insights and editorial assistance. P.P. managed the mice. P.P. and B.S. conducted and wrote about the ChIP experiments.

Funding
The study was supported by the Academy of Finland [grant number 265620/13]; the Sigrid Jusélius Foundation; the Finska Läkaresällskapet; the Magnus Ehrnrooth Foundation; Liv och Hälsa; and the Stockmann Foundation.
Abbreviations
AR, androgen receptor; AZIN1, antizyme inhibitor 1; AZIN2, antizyme inhibitor 2; ChiP, chromatin immunoprecipitation; EST, expressed sequence tag; IVT, in-vitro translation; OAZ, ornithine decarboxylase antizyme; ODC, ornithine decarboxylase; ODCrp, ornithine decarboxylase-related protein; qPCR, quantitative polymerase chain reaction; T, testosterone.

References
1 Kahana, C. (2009) Regulation of cellular polyamine levels and cellular proliferation by antizyme and antizyme inhibitor. Essays Biochem. 46, 47–61
2 Pegg, A.E. (2009) Mammalian polyamine metabolism and function. IUBMB Life 61, 880–894
3 Thomas, T. and Thomas, T.J. (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell. Mol. Life Sci. 58, 244–258
4 Hayashi, S. and Murakami, Y. (1995) Rapid and regulated degradation of ornithine decarboxylase. Biochem. J. 306, 1–10
5 Pegg, A.E. (2006) Regulation of ornithine decarboxylase. J. Biol. Chem. 281, 14529–14532
6 Tobias, K.E. and Kahana, C. (1993) Intersubunit location of the active site of mammalian ornithine decarboxylase as determined by hybridization of site-directed mutants. Biochemistry 5842–5847
7 Grishin, N.V., Osterman, A.L., Brooks, H.B., Phillips, M.A. and Goldsmith, E.J. (1999) X-ray structure of ornithine decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with alpha-difluoromethylornithine. Biochemistry 38, 15174–15184
8 Kern, A.D., Oliveira, M.A., Coffino, P. and Hackert, M.L. (1999) Structure of mammalian ornithine decarboxylase at 1.6 Å resolution: stereochemical implications of PLP-dependent amino acid decarboxylases. Structure 7, 567–581
9 Coleman, C.S., Stanley, B.A., Viswanath, R. and Pegg, A.E. (1994) Rapid exchange of subunits of mammalian ornithine decarboxylase. J. Biol. Chem. 269, 3155–3158
10 Feng, W.F., Heller, J.S. and Canellakis, E.S. (1976) The appearance of an ornithine decarboxylase inhibitory protein upon the addition of putrescine to cell cultures. Biochim. Biophys. Acta 428, 466–465
11 Heller, J.S., Feng, W.F. and Canellakis, E.S. (1976) Induction of a protein inhibitor to ornithine decarboxylase by the end products of its reaction. Proc. Natl. Acad. Sci. U.S.A. 73, 1858–1862
12 Kahana, C. (2009) Antizyme and antizyme inhibitor, a regulatory tango. Cell Mol. Life Sci. 66, 2479–2488
13 Li, X. and Coffino, P. (1992) Regulated degradation of ornithine decarboxylase requires interaction with the polyamine-inducible protein antizyme. Mol. Cell Biol. 12, 3556–3562
14 Li, X. and Coffino, P. (1993) Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein. Mol. Cell Biol. 13, 2377–2383
15 Mamroud-Kidron, E., Omer-Itsicovich, M., Bercovich, Z., Tobias, K.E., Rom, E. and Kahana, C. (1994) A unified pathway for the degradation of ornithine decarboxylase in reticuloocyte lysate requires interaction with the polyamine-induced protein, ornithine decarboxylase antizyme. Eur. J. Biochem. 226, 547–554
16 Murakami, Y., Matsufuji, S., Kameji, T., Hayashi, S., Igarashi, K., Tamura, T. et al. (1992) Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360, 597–599
17 Murakami, Y. and Hayashi, S. (1985) Role of antizyme in degradation of ornithine decarboxylase in HT cells. Biochem. J. 226, 893–896
18 Murakami, Y., Ichiba, T., Matsufuji, S. and Hayashi, S. (1996) Cloning of antizyme inhibitor, a highly homologous protein to ornithine decarboxylase. J. Biol. Chem. 271, 3340–3342
19 Cohavi, O., Tobi, D. and Schreiber, G. (2009) Docking of antizyme to ornithine decarboxylase and antizyme inhibitor using experimental mutant and double-mutant cycle data. J. Mol. Biol. 390, 503–515
20 Fujita, K., Murakami, Y. and Hayashi, S. (1982) A macromolecular inhibitor of the antizyme to ornithine decarboxylase. Biochem. J. 204, 647–652
21 Nilsson, J., Grahn, B. and Heby, O. (2000) Antizyme inhibitor is rapidly induced in growth-stimulated mouse fibroblasts and releases ornithine decarboxylase from antizyme suppression. Biochem. J. 346, 699–704
22 Bercovich, Z. and Kahana, C. (2004) Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme. J. Biol. Chem. 279, 50497–50502
23 Kanerva, K., Makitie, L.T., Pelander, A., Heiskala, M. and Andersson, L.C. (2008) Human ornithine decarboxylase parologue (ODCrp) is an antizyme inhibitor but not an arginine decarboxylase. Biochem. J. 409, 187–192
24 Ivanov, I.P., Firth, A.E. and Atkins, J.F. (2010) Recurrent emergence of catalytically inactive ornithine decarboxylase homologous forms that likely have regulatory function. J. Mol. Evol. 70, 289–302
25 Isomaa, V., Pajunen, A.E., Bardin, C.W. and Janne, O.A. (1982) Nuclear androgen receptors in the mouse kidney: validation of a new assay. Endocrinology 111, 833–843
26 Sahu, B., Laakso, M., Ovaska, K., Mirtti, T., Lundin, J., Rannikko, A. et al. (2011) Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 30, 3962–3976
27 Zhang, Y., Liu, T., Meyer, C.A., Eechkoute, J., Johnson, D.S., Bernstein, B.E. et al. (2008) Model-based analysis of ChiP-Seq (MACS). Genome Biol. 9, R137
28 Robinson, J.T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G. et al. (2011) Integrative genomics viewer. Nat. Biotechnol. 29, 24–26
29 Makitie, L.T., Kanerva, K., Polvikoski, T., Paetau, A. and Andersson, L.C. (2010) Brain neurons express ornithine decarboxylase-activating antizyme inhibitor 2 with accumulation in Alzheimer’s disease. Brain Pathol. 20, 571–580

© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
30 Pitkanen, L.T., Heiskala, M. and Andersson, L.C. (2001) Expression of a novel human ornithine decarboxylase-like protein in the central nervous system and testes. Biochem. Biophys. Res. Commun. 287, 1051–1057

31 Taira, S. and Coffino, P. (1992) Dominant negative mutants of ornithine decarboxylase. J. Biol. Chem. 267, 23057–23062

32 Jackson, L.K., Goldsmith, E.J. and Phillips, M.A. (2003) X-ray structure determination of Trypanosoma brucei ornithine decarboxylase bound to D-ornithine and to G418: insights into substrate binding and ODC conformational flexibility. J. Biol. Chem. 278, 22037–22043

33 Jackson, L.K., Brooks, H.B., Osterman, A.L., Goldsmith, E.J. and Phillips, M.A. (2000) Altering the reaction specificity of eukaryotic ornithine decarboxylase. Biochemistry 39, 11247–11257

34 Myers, D.P., Jackson, L.K., Ipe, V.G., Murphy, G.E. and Phillips, M.A. (2001) Long-range interactions in the dimer interface of ornithine decarboxylase are important for enzyme function. Biochemistry 40, 13230–13236

35 Kidron, H., Repo, S., Johnson, M.S. and Salminen, T.A. (2007) Functional classification of amino acid decarboxylases from the alanine racemase structural family by phylogenetic studies. Mol. Biol. Evol. 24, 79–89

36 Su, K.L., Liu, Y.F., Hung, H.C. and Liu, G.Y. (2009) Critical factors determining dimerization of human antizyme inhibitor. J. Biol. Chem. 284, 26768–26777

37 Liu, Y.C., Hsu, D.H., Huang, C.L., Liu, Y.L., Liu, G.Y. and Hung, H.C. (2011) Determinants of the differential antizyme-binding affinity of ornithine decarboxylase. PLoS ONE 6, e26835

38 Liu, Y.C., Liu, Y.L., Su, J.Y., Liu, G.Y. and Hung, H.C. (2011) Critical factors governing the difference in antizyme-binding affinities between human ornithine decarboxylase and antizyme inhibitor. PLoS ONE 6, e19253

39 Rogers, S., Wells, R. and Rechsteiner, M. (1986) Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 234, 364–368

40 Ghoda, L., Sidney, D., Macrae, M. and Coffino, P. (1992) Structural elements of ornithine decarboxylase required for intracellular degradation and polyamine-dependent regulation. Mol. Cell Biol. 12, 2178–2185

41 Almrud, J.J., Oliveira, M.A., Kern, A.D., Grishin, N.V., Phillips, M.A. and Hackert, M.L. (2000) Crystal structure of human ornithine decarboxylase at 2.1 A resolution: structural insights to antizyme binding. J. Mol. Biol. 295, 7–16

42 National Center for Biotechnology Information, UniGene, EST Profile – Mm.387701, Available at: http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.387701

43 Pajunen, A.E., Isomaa, V.V., Janne, O.A. and Bardin, C.W. (1982) Androgenic regulation of ornithine decarboxylase activity in mouse kidney and its relationship to changes in cytosol and nuclear androgen receptor concentrations. J. Biol. Chem. 257, 8190–8198

44 Isomaa, V.V., Pajunen, A.E., Bardin, C.W. and Janne, O.A. (1983) Ornithine decarboxylase in mouse kidney. Purification, characterization, and radioimmunochemical determination of the enzyme protein. J. Biol. Chem. 258, 6735–6740

45 Kontula, K.K., Torkkeli, T.K., Bardin, C.W. and Janne, O.A. (1984) Androgen induction of ornithine decarboxylase mRNA in mouse kidney as studied by complementary DNA. Proc. Natl. Acad. Sci. U.S.A 81, 731–735

46 Pihlajamaa, P., Sahu, B., Lyly, L., Altimomi, V., Hautaniemi, S. and Janne, O.A. (2014) Tissue-specific pioneer factors associate with androgen receptor cistromes and transcription programs. EMBO J. 33, 312–326

47 Crozat, A., Palvimo, J.J., Julkunen, M. and Janne, O.A. (1992) Comparison of androgen regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase gene expression in rodent kidney and accessory sex organs. Endocrinology 130, 1131–1144

48 Bardin, C.W. and Catterall, J.F. (1981) Testosterone: a major determinant of extragenital sexual dimorphism. Science 211, 1285–1294

49 Tovar, A., Sanchez-Capelo, A., Cremades, A. and Penafiel, R. (1995) An evaluation of the role of polyamines in different models of kidney hypertrophy in mice. Kidney Int. 48, 731–737

50 Pihlajamaa, P., Sahu, B. and Janne, O.A. (2015) Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling. Endocr. Rev. 36, 357–384

51 Pitz, R.B., Steglich, C. and Scheffler, I.E. (1990) Molecular and genetic characterization of an ornithine decarboxylase-deficient Chinese hamster cell line. J. Biol. Chem. 265, 8880–8886

52 Osterman, A.L., Kinch, L.N., Grishin, N.V. and Phillips, M.A. (1995) Acidic residues important for substrate binding and cofactor reactivity in eukaryotic ornithine decarboxylase identified by alanine scanning mutagenesis. J. Biol. Chem. 270, 11797–11802

53 Davis, R.H., Morris, D.R. and Coffino, P. (1992) Sequestered end products and enzyme regulation: the case of ornithine decarboxylase. Microbiol. Rev. 56, 280–290